FZD7 regulates BMSCs-mediated protection of CML cells

Na Liu; Shaolei Zang; Yan Liu; Yingqiao Wang; Wei Li; Qiang Liu; Min Ji; Daoxin Ma; Chunyan Ji

doi:10.18632/oncotarget.6742

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

FZD7 regulates BMSCs-mediated protection of CML cells

Na Liu, Shaolei Zang, Yan Liu, Yingqiao Wang, Wei Li, Qiang Liu, Min Ji, Daoxin Ma and Chunyan Ji _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2016; 7:6175-6187. https://doi.org/10.18632/oncotarget.6742

Metrics: PDF 2151 views | HTML 2382 views | ?

Abstract

Na Liu1,*, Shaolei Zang1,*, Yan Liu1, Yingqiao Wang1, Wei Li1, Qiang Liu2, Min Ji1, Daoxin Ma1, Chunyan Ji1

1Department of Hematology Qilu Hospital, Shandong University, Ji’nan 250012, China

2Medical Research Center, Shandong Provincial Qianfoshan Hospital, Shandong University, Ji’nan 250014, China

*These authors contributed equally to this work

Correspondence to:

Chunyan Ji, e-mail: [email protected]

Keywords: FZD7, CML, BMSCs, imatinib sensitivity, Wnt signaling pathway

Received: June 23, 2015 Accepted: December 09, 2015 Published: December 23, 2015

ABSTRACT

Inspite of effective treatment with imatinib (IM), chronic myeloid leukemia (CML) is still an incurable disease. Some patients became refractory because of IM resistance. Bone marrow mesenchymal stem cells (BMSCs) have been implicated a role in promoting CML cells’ resistance against IM treatment. The detailed molecular mechanisms, however, remain largely unknown. In this study, we found that BMSCs increased the expression of FZD7 and activated Wnt/β-catenin signaling pathway in CML cells. BMSCs from CML patients showed increased efficiency to accelerate CML cell proliferation, enhance the drug resistance of K562 cells and up-regulate the expression of FZD7. Antagonism of FZD7 expression by shRNA significantly suppressed proliferation and increased IM sensitivity of CML cells co-cultured with BMSCs cells. Our findings suggest that FZD7, involved in canonical Wnt signaling pathway, plays a critical role in mediating BMSCs-dependent protection of CML cells, and potentially provide a novel therapeutic target for CML.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 6742

Publication Alerts

Post-Publication Promotion

Publication Discount

Research Papers:

FZD7 regulates BMSCs-mediated protection of CML cells

Abstract